This review focused on the progress in recombinant TRAIL fusion proteins, including updates on their clinical trials in order to provide more rational and effective fusion strategies to enhance the efficacy of recombinant sTRAIL and facilitate its development for cancer therapy. This evidence concerns the gene TNFSF10 and cancer.